About Tirzepatide Peptide — An Annotated Bibliography

What this site is

Tirzepatide Peptide is, at heart, an annotated bibliography of one compound. It works through the peer-reviewed literature on tirzepatide — the dual GIP/GLP-1 receptor agonist the U.S. FDA has approved for type 2 diabetes, chronic weight management, and obstructive sleep apnea — and summarises each source in plain language, with the citation kept in view. It is a place to read the record, not a place to obtain the drug: there is no clinic behind it, no prescriber, no pharmacy, and nothing for sale.

The 'peptide' in the name is simple description — tirzepatide is a peptide, a 39-amino-acid synthetic molecule — and nothing more. It signals no medical scope and no service. The annotator's job here is to read carefully, summarise faithfully, and hand the reader the reference so they can go to the source themselves.

How we work

Every quantitative claim on this site is cited to a specific peer-reviewed publication, clinical-trial report, or regulatory document. Mechanism claims are grounded in the published receptor-pharmacology literature (Coskun et al. 2018, Willard et al. 2020, Novikoff et al. 2021, Sun et al. 2022, Douros et al. 2024). Clinical-outcome claims are grounded in the SURPASS and SURMOUNT phase 3 trial reports (NEJM, Lancet, JAMA) and systematic reviews. Safety claims are grounded in meta-analyses and FDA labelling.

We do not invent citations. We do not recommend doses or treatment decisions. We do not mention competitor brand names. We do not link to vendors, pharmacies, or clinical-service providers.

The human-layer material on the effects page — community-reported benefits and side effects — is clearly labelled as anecdotal, not clinical evidence, and is drawn from structured patient-interview research and pharmacovigilance data, not invented or extrapolated.

What we are not

This is a bibliography, not a bedside. Tirzepatide Peptide gives no consultations, writes no prescriptions, and offers no monitoring; it makes no judgement about whether the drug suits any particular reader. It sells nothing and refers to no vendor, pharmacy, or clinical service.

Anyone actually considering tirzepatide — or any prescription medicine — is best served by a licensed clinician, not by a website. The studies summarised here are public; the clinical judgement about applying them to a real person belongs to a qualified professional who can weigh that person's circumstances.